- Home
- PBFS vs CADL Comparison
PBFS vs CADL Comparison
Compare PBFS & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PBFS | CADL |
|---|---|---|
| Founded | 1889 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 333.8M | 339.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PBFS | CADL |
|---|---|---|
| Price | $13.35 | $5.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.43 |
| AVG Volume (30 Days) | 18.5K | ★ 901.3K |
| Earning Date | 01-29-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.64 | N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $91,717,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.02 | ★ N/A |
| Revenue Growth | ★ 17.04 | N/A |
| 52 Week Low | $10.60 | $4.25 |
| 52 Week High | $14.94 | $13.68 |
Technical Indicators
Market Signals| Indicator | PBFS | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 40.88 | 52.27 |
| Support Level | $13.05 | $5.45 |
| Resistance Level | $13.68 | $5.78 |
| Average True Range (ATR) | 0.38 | 0.31 |
| MACD | -0.13 | -0.06 |
| Stochastic Oscillator | 8.97 | 46.74 |
Price Performance
Historical ComparisonAbout PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.